Axol Bioscience appoints new scientific advisory board member

Axol Bioscience has announced the appointment of Dr Paul Andrews as the newest member of its scientific advisory board.

Dr Andrews is a recognised expert in the industrial application of stem cells in phenotypic screening, having previously used this platform to identify agents that control the fate of cells.

He serves as director of operations at the National Phenotypic Screening Centre and sits on the editorial board for current research in drug discovery at the Royal Society of Biology, as well as boasting more than 20 years of postdoctoral research experience in cell and molecular biology.

In his new role with Axol, he will help the company ensure its commercially available human primary and induced pluripotent stem cell-derived cells (iPSCs) continue to enable the development of pathophysiologically-relevant systems for industrial and academic research.

Dr Yichen Shi, chief executive officer of Axol Bioscience, said Dr Andrews will be an asset to the company because of "his interdisciplinary approach and experience using human iPSCs and embryonic stem cells for high-throughput phenotypic drug screening".